• Active, not recruiting

NCT04035226 - Study of Real-life Current Standards of Care in Patients With RRMM with 3 prior lines

Updated: Oct 24

LocoMMotion

Relapsed & Refractory Multiple Myeloma

locoMMotion

NCT04035226: A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment (LocoMMotion)


The purpose of this study is to assess the safety and clinical response including overall response rate (ORR) of real-life standard-of-care (SOC) treatments under routine clinical practice, over a 24-month period, in patients with relapsed/refractory multiple myeloma (RRMM).


Sponsor

Janssen-Cilag Ltd.


Collaborator

Legend Biotech


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT04035226

Official Title: A Prospective, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMID, and CD38 Monoclonal Antibody Treatment

First Posted : July 29, 2019

Click here to see details on ClinicalTrials.gov

 

Observational Study

No intervention will be administered as a part of this study.


Patients with relapsed/refractory multiple myeloma (RRMM) receiving antimyeloma treatment as standard of care (SOC) under routine clinical practice will be observed. The main source of data collection will be medical records of each patient.

 

- Multiple Locations

- International Study

 

Leukemia: 2022 Mar 24 - LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

Abstract: The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action.

Click here for details

 

Efficacy of Teclistimab versus current treatments in patients with triple-class exposed RR myeloma - YouTube

June 28, 2022

International Myeloma Foundation

Subscribe to our channel: https://www.youtube.com/c/IMFMyeloma

 

Locations

United States, Arizona

United States, California

United States, Florida

United States, Illinois

United States, Michigan

United States, Missouri

United States, Nevada

United States, New Jersey

United States, New York

United States, Ohio

Europe

United Kingdom

France

Germany

Italy

Spain

Netherlands

Belgium

Poland

Asia

Russian Federation








Posts Archive